Calcineurin inhibitor resistant immune cells for use in adoptive cell transfer therapy
AssigneeUniversitäT Basel
InventorsLukas JEKER, Marianne DÖLZ
Life of this patent
Estimating the term…
Abstract
The present invention relates to immune cells in which the regulatory activity of miR-17˜92 cluster or paralogs thereof is increased to confer calcineurin inhibitor resistance. In particular said immune cell is engineered to overexpress at least one mi RNA of miR-17˜92 cluster or paralogs thereof or to inactivate at least one miR-17˜92 cluster target gene to confer calcineurin inhibitor resistance. Particularly, the present invention relates to the use of calcineurin inhibitor-resistant immune cells in combination with calcineurin inhibitor in adoptive cell transfer therapy in a patient in need thereof.
Claims17
A method for adoptive cell transfer therapy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a calcineurin inhibitor (CNI)-resistant immune cell in which regulatory activity of the miR-17˜92 cluster or paralogs thereof is increased wherein said CNI-resistant immune cell is administered in combination with a CNI in said subject.
A method of treating a cancer, an autoimmune disease, an inflammatory disease, an infectious disease, a disease requiring hematopoietic stem cells transplantation (HSCT) or organ rejection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a calcineurin inhibitor (CNI)-resistant immune cell in which regulatory activity of the miR-17˜92 cluster or paralogs thereof is increased, and wherein said (CNI)-resistant immune cell is administered to the subject in combination with a CNI.
A pharmaceutical composition comprising a CNI-resistant immune cell in which regulatory activity of the miR-17˜92 cluster or paralogs thereof is increased, a calcineurin inhibitor and a pharmaceutically acceptable carrier.
The A method for adoptive cell transfer therapy in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising a CNI-resistant immune cell in which regulatory activity of the miR-17˜92 cluster or paralogs thereof is increased, a calcineurin inhibitor and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.